A. Oliver Sartor
Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.
Overview
Oliver Sartor was co-principal investigator of VISION, which showed 177Lu-PSMA-617 improves survival in PSMA-positive metastatic castration-resistant prostate cancer and led to Pluvicto's approval, and was a lead investigator of PSMAfore, which moved the therapy before chemotherapy. He also co-led ALSYMPCA (radium-223). He directs the radiopharmaceutical trials programme at Mayo Clinic.
An alpha-emitting radioactive drug built on a PSMA-targeting antibody, rather than the small-molecule ligands used in existing PSMA therapies, was safe enough to move into further testing and shrank PSA in roughly a third to a half of heavily pre-treated men, including some whose cancer had already stopped responding to lutetium-177 PSMA therapy.
For men who still have a working hormone treatment option but whose cancer is progressing, offering the PSMA radioligand therapy sooner - before chemotherapy - delayed disease progression, though it did not clearly extend how long men lived once the very high rate of patients switching over is accounted for.
Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).
Similar pages
not linked directly; found by shared links- PersonMichael J. Morris
Shares Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617, PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC, PSMAfore, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer.
- PersonLouise Emmett
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters) and the tags prostate, radioligand.
- PersonKen Herrmann
Shares PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, VISION, PSMA and the tag radioligand.
- PersonChris C. Parker
Shares Radium-223, Prostate cancer and the tags prostate, trialist.
- PersonJonathan R. Strosberg
Shares Radioligand therapy (beta emitters), Lutetium-177 and the tags radioligand, trialist.
- PersonKarim Fizazi
Shares ALSYMPCA, PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Radium-223.
- PersonScott T. Tagawa
Shares VISION, Lutetium-177 vipivotide tetraxetan, Lutetium-177 and the tag prostate.
- PersonRahul Aggarwal
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).